Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Single-Handed Suturing Medical Device Developed By Mellon Medical

XTALKS VITALS NEWS

Medical Device

The Switch medical device has a range of applications, from stitching-up blood vessels to closing incisions made in the skin, and could save surgeons considerable time in the operating room.

Tweetables from this article:

Tweet: Mellon Medical's Switch #medicaldevice requires only a single hand to operate http://ctt.ec/FwI3h+ Mellon Medical's Switch medical device requires only a single hand to operate.

Share this!

October 5, 2016 | by Sarah Hand, M.Sc.

Closing a patient up after surgery is one of the most simple, yet time-consuming tasks performed by surgeons. Dutch medical device company, Mellon Medical, has set out to make this laborious process more efficient by developing their new suturing device, Switch, which requires only one hand to operate.

The Switch medical device has a range of applications, from stitching-up blood vessels to closing incisions made in the skin, and could save surgeons considerable time in the operating room. While the first iteration of this suturing medical device is 8 cm long and indicated for use during kidney transplants, peripheral bypass procedures and carotid artery surgery, the company plans to eventually release multiple sizes of the tool meant to perform different functions.

The medical device is designed to look like a pair of bent tweezers with a small needle and attached suture positioned directly at the tip of the Switch. With every manipulation of the tweezers, the needle is passed from one point to the other.



As the Switch requires only a single hand to operate, a surgeon’s non-dominant hand can be freed-up to perform other tasks such as presenting the tissue. Since the needle and attached suture are passed linearly between the tweezer tips, the surgeon does not need to focus on catching the needle as it passes through the tissue.

The result is a much more efficient way of suturing in the operating room. According to a press release issued by Mellon, the Switch is two times faster than conventional suturing methods.

As yet, the medical device is not approved by regulators, but Mellon plans to apply for both CE mark and US Food and Drug Administration (FDA) approval in the next several years. Their initial launch is set to be focused on vascular surgery but Mellon says the technology can be applied to a number of other disciplines, including neurosurgery, urology and gynecology.


Keywords: Medical Device, Surgery, FDA


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.